Li Ke, Xu Heng, Liu Ning Fei, Sadigh Parviz, Evans Verity, Zhang Yi Xin
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Plastic Reconstructive Surgery, The Royal London Hospital, London, UK.
Arch Gynecol Obstet. 2017 Jun;295(6):1441-1450. doi: 10.1007/s00404-017-4371-3. Epub 2017 Apr 22.
Lower extremity lymphedema is regarded as a relatively common postoperative complication and is often accompanied with dermatolymphangioadenitis (DLA). This study combines clinical assessment and laboratory investigation to explore therapeutic effects of far-infrared radiation (FIR) therapy for chronic lower extremity lymphedema accompanied with DLA, occurring after gynecological tumor resection.
Patients who met inclusion and exclusion criteria would be enrolled. They received regular sessions using the FIR therapy machine over the 4-week treatment course. Clinical and laboratory outcome measures were carried out before and after treatment. Clinical outcome measures included DLA seizure frequency (episodes/year), patients' subjective feedback for lymphedema-related symptoms and quality of life (QOL). Laboratory outcome measures included bacterial cultures and concentrations of inflammatory cytokines: IL-1β, IL-2, IL-4, IL-10, IL-12, IL-18, TNF-α, TNF-β, caspase-1 and INF-γ, detected in serum and local lymphedema tissue fluid samples using protein microarray and ELISA.
Between 2012 and 2016, a total of 120 female patients were screened for study enrollment. Sixty-four recruited patients underwent clinical evaluation both before FIR radiation therapy and 1 year after a single course of FIR radiation therapy. Eleven patients (17.2%), randomly chosen from the study group, underwent additional laboratory analysis of blood and local lymphedema tissue fluid samples. The frequency of DLA decreased following treatment (p < 0.001). Fifty patients (78%) did not experience a single episode of DLA recurrence in the year subsequent to treatment. The efficiency rate calculated using DLA frequencies was greater than 50% for 63 (98%) patients following treatment. Patients reported a subjective decrease in lymphedema-related symptoms (p < 0.05). Patients' QOL scores were higher after treatment (p < 0.001). Laboratory analysis showed an elevation in serum concentration of IL-1β after FIR therapy (p < 0.05) and reduced local tissue fluid concentrations of inflammatory cytokines IL-2, IL-10 and IL-18 (p < 0.05). Bacterial culture results before and after treatment were both negative.
FIR radiation therapy provides an effective treatment modality for patients with chronic lymphedema accompanied with DLA that develops secondarily to treatment of gynecological malignancies, whose therapeutic effects may be due to reduced immune dysfunction within local lymphedema tissues.
下肢淋巴水肿被视为一种相对常见的术后并发症,常伴有皮肤淋巴管炎(DLA)。本研究结合临床评估和实验室调查,探讨远红外辐射(FIR)疗法对妇科肿瘤切除术后发生的伴有DLA的慢性下肢淋巴水肿的治疗效果。
符合纳入和排除标准的患者将被纳入研究。在为期4周的治疗过程中,他们使用FIR治疗机进行定期治疗。在治疗前后进行临床和实验室结果测量。临床结果测量包括DLA发作频率(发作次数/年)、患者对淋巴水肿相关症状的主观反馈以及生活质量(QOL)。实验室结果测量包括细菌培养以及炎症细胞因子的浓度:使用蛋白质微阵列和酶联免疫吸附测定法在血清和局部淋巴水肿组织液样本中检测白细胞介素-1β(IL-1β)、白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、白细胞介素-12(IL-12)、白细胞介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)、肿瘤坏死因子-β(TNF-β)、半胱天冬酶-1(caspase-1)和干扰素-γ(INF-γ)。
在2012年至2016年期间,共筛选了120名女性患者纳入研究。64名入选患者在FIR放射治疗前和单疗程FIR放射治疗1年后均接受了临床评估。从研究组中随机选择11名患者对血液和局部淋巴水肿组织液样本进行了额外的实验室分析。治疗后DLA频率降低(p<0.001)。50名患者(78%)在治疗后的一年中未经历一次DLA复发。使用DLA频率计算的有效率在治疗后63名(98%)患者中大于50%。患者报告淋巴水肿相关症状主观减轻(p<0.05)。治疗后患者的QOL评分更高(p<0.001)。实验室分析显示FIR治疗后血清中IL-1β浓度升高(p<0.05),局部组织液中炎症细胞因子IL-2、IL-10和IL-18浓度降低(p<0.05)。治疗前后细菌培养结果均为阴性。
FIR放射治疗为伴有继发于妇科恶性肿瘤治疗后的DLA的慢性淋巴水肿患者提供了一种有效的治疗方式,其治疗效果可能归因于局部淋巴水肿组织内免疫功能障碍的减轻。